Rickmann Annekatrin, Schulz Andre, Bohrer Bianca, Waizel Maria, Bisorca-Gassendorf Lukas, Al-Nawaiseh Sami, Wakili Phillip, Januschowski Kai
Ophthalmology, Eye Clinic, Knappschaft Hospital Saar, Sulzbach, DEU.
Research, Pharmbiotec GmbH, Saarbrücken, DEU.
Cureus. 2021 Oct 10;13(10):e18645. doi: 10.7759/cureus.18645. eCollection 2021 Oct.
Objectives The purpose of this study is to compare the risks of novel postoperative curcumin infusion in patients with increased proliferative vitreoretinal retinopathy (PVR) after retinal detachment with steroid infusion or no treatment. Methods This was a prospective, non-randomized pilot study of 15 eyes of 15 patients (mean age 68 ± 7 years) with retinal detachment, macula off, and flare >15 pc/ms. Postoperatively, the patients received either curcumin-HSA (human serum albumin) infusion (C, n=5), prednisolone infusion (P, n=5), or no therapy (N, n=5) for three days. The outcome measures included postoperative PVR rate, the number of vitreoretinal surgeries (VRS) required, epiretinal membrane development, and visual acuity (VA). Results All patients had a preoperative VA of hand movements, macula-off detachment situation, and two quadrants rhegmatogenous retinal detachment. Patients underwent VRS at a mean time of 5.6 ± 1.5 (C), 4.9 ± 2.0 (P), 4.7 ± 1.2 (N) days after first recognized symptoms. Postoperative PVR developed just in one eye (P) after 16 days and required VRS due to PVR retinal detachment. The remaining 14 patients of group C and N did not develop PVR. BCVA improved six months post surgery to 0.56 ± 0.31 (P), 0.53 ± 0.19 (D), 0.53 ± 0.17 (N) logMAR. There were no side effects nor complications related to the postoperative infusions. Conclusions In this pilot study, we demonstrated that a postoperative application of curcumin infusion is a safe option in patients with an increased risk of PVR. Whether or not PVR can be reduced by curcumin infusion would require to be investigated in larger, randomized clinical trials.
目的 本研究旨在比较视网膜脱离后增殖性玻璃体视网膜病变（PVR）增加的患者接受新型术后姜黄素输注与类固醇输注或不治疗的风险。方法 这是一项前瞻性、非随机的试点研究，研究对象为15例（平均年龄68±7岁）视网膜脱离、黄斑脱离且闪光>15 pc/ms的患者的15只眼。术后，患者接受姜黄素-人血清白蛋白（HSA）输注（C组，n = 5）、泼尼松龙输注（P组，n = 5）或不进行治疗（N组，n = 5），持续三天。观察指标包括术后PVR发生率、所需玻璃体视网膜手术（VRS）次数、视网膜前膜形成情况和视力（VA）。结果 所有患者术前视力均为手动，黄斑脱离，两个象限孔源性视网膜脱离。患者在首次出现症状后平均5.6±1.5天（C组）、4.9±2.0天（P组）、4.7±1.2天（N组）接受VRS。术后仅1例P组患者在16天后发生PVR，并因PVR视网膜脱离需要进行VRS。C组和N组其余14例患者未发生PVR。术后6个月最佳矫正视力（BCVA）提高到0.56±0.31（P组）、0.53±0.19（D组）、0.53±0.17（N组）logMAR。术后输注未出现副作用或并发症。结论 在本试点研究中，我们证明了术后应用姜黄素输注对于PVR风险增加的患者是一种安全的选择。姜黄素输注是否能降低PVR需要在更大规模的随机临床试验中进行研究。
